Fig. 7: Combination treatment of 2DG and anti-PD-L1 suppressed ovarian tumors by promoting CD8⁺ T cell activity.

a Signaling pathways that are enriched in the combination treatment group compared to the anti-PD-L1 treatment group of KPCA tumors based on single cell RNA-seq analysis. For single cell RNA-seq, n = 1 mouse from each of the indicated groups. b IFNγ expression of CD8⁺ T cells in each group of KPCA tumors based on single cell RNA-seq analysis. P-values were calculated using two-tailed t-test. For single cell RNA-seq, n = 1 mouse from each of the indicated groups. c FACS analysis of IFNγ expressed CD8⁺ T cells in each group of KPCA tumors. n = 5 mice. Two-tailed P-values were calculated by ANOVA corrected by the Benjamini, Krieger and Yekutieli method to generate q-values. Error bars represent mean with SEM. d Inhibiting branched N-glycans sensitizes HR-proficient ovarian tumors to anti-PD-1 and anti-PD-L1 immunotherapies. weight and images of orthotopic tumors formed by HR-proficient KPCA cells in C57BL/6 mice following the indicated treatments with 2DG, anti-PD-1 antibody, anti-PD-L1 antibody or in combination. n = 5 mice. Two-tailed P-values were calculated by ANOVA corrected by the Benjamini, Krieger and Yekutieli method to generate q-values. Error bars represent mean with SEM. e, f Same as (Fig. 6b), but the mice were randomized into three indicated treatment groups. After completing treatment, tumors were harvested and weighed (Two-tailed P-values were calculated by ANOVA corrected by the Benjamini, Krieger and Yekutieli method) (e) or mice were followed for survival and the Kaplan–Meier survival curves for each of the indicated groups are shown (f) (n = 5 mice/group) (P-values were calculated by Log-rank test). Error bars represent mean with SEM. Source data are provided as a Source Data file.